Dr Reddy's Q4FY25 Preview: Consumer wellness may lift topline; US generics, gRevlimid to weigh on momentum

Dr Reddy’s Laboratories will report its Q4 FY25 earnings on May 9. As per analyst recommendations on Bloomberg, the pharma company has been rated 15 Buys, 11 Holds, 14 Sells. The company's financial health, as reflected in its estimated rev
Read more...